A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma
2008; Lippincott Williams & Wilkins; Volume: 26; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2008.26.15_suppl.19087
ISSN1527-7755
AutoresPablo M. Bedano, SM Perkins, Matthew Burns, Ketty Kessler, Rich Nelson, B. P. Schneider, L. Risley, S. Dropcho, P. J. Loehrer,
Tópico(s)Cancer Treatment and Pharmacology
Resumo19087 Background: Few prospective trials have been conducted in patients (pts) with thymic malignancies. Angiogenesis and EGFR overexpression seems to play an important role in the pathogenesis of invasive thymoma (THY) and thymic (TC) carcinoma. This phase II trial studied the efficacy and safety of the novel combination of erlotinib (E) and bevacizumab (BEV) on pretreated pts with progressive malignant thymic tumors. Methods: From September, 2006 to August, 2007,18 previously treated pts with advanced THY or TC were treated with E 150 mg by mouth every day and BEV 15 mg/kg IV, cycle repeated every 21 days. DNA was extracted from whole blood to study associations between outcome and variability in single nucleotide polymorphisms from angiogenesis genes. Patients who achieved a complete (CR), partial response (PR), stable disease (SD) after 2 treatment cycles, were continued on BEV and E, until progression or unacceptable toxicity. Pts receiving at least one cycle were evaluated for response. Results: Profile of 18 pts included: histology (THY=11, TC=7); M:F = 8:10; 5 pts had received prior radiation therapy. Of pts treated, none achieved CR, 11 pts (60%) achieved SD, and 7 (40%) had PD. There were no grade 4 toxicities or deaths. The most common grade 3 toxicities were: acneform rash (2), dyspnea (2), fatigue (1), pericardial tamponade (1) and aortic insufficiency (1). The median survival time has not been reached. Conclusions: The combination of E and BEV has limited activity in thymic malignancies, but has a well tolerated side effect profile. The high incidence of SD status noted most likely reflects the inherent tumor biology, but an impact of the agents cannot be ruled out. Other therapeutic approaches are warranted for this population of pts. No significant financial relationships to disclose.
Referência(s)